Abstract
Ischemic colitis (CI) is a common form of ischemic injury, which evolves as a consequence of decreased arterial blood flow to the colon. In general, CI is attributed to an elderly with multiple comorbidities; however, it may also occur in young or middle-aged individuals. The etiology of CI is multifactorial and the clinical presentation varies upon the severity of deprivation of the intestinal blood flow, and the development of the microvasculature plexus. Multiple case reports have associations with medications, vascular disorders, pathogens and hematologic diseases. Occlusive and nonocclusive diseases are the major mechanisms, which are simultaneously the causative factor of intestinal ischemia. In this review, we discuss major factors predisposing to occurrence of CI and analyze the mechanisms of action of several classes of medications currently used. We also suggest possible therapies and discuss the latest reports, which may lead to the discovery of novel pharmacological targets for future anti-CI drugs to be used in the clinical treatment.
Keywords: Intestinal ischemia, ischemic colitis, management, risk factors.
Current Drug Targets
Title:Ischemic Colitis: Current Diagnosis and Treatment
Volume: 16 Issue: 3
Author(s): Paula Mosinska and Jakub Fichna
Affiliation:
Keywords: Intestinal ischemia, ischemic colitis, management, risk factors.
Abstract: Ischemic colitis (CI) is a common form of ischemic injury, which evolves as a consequence of decreased arterial blood flow to the colon. In general, CI is attributed to an elderly with multiple comorbidities; however, it may also occur in young or middle-aged individuals. The etiology of CI is multifactorial and the clinical presentation varies upon the severity of deprivation of the intestinal blood flow, and the development of the microvasculature plexus. Multiple case reports have associations with medications, vascular disorders, pathogens and hematologic diseases. Occlusive and nonocclusive diseases are the major mechanisms, which are simultaneously the causative factor of intestinal ischemia. In this review, we discuss major factors predisposing to occurrence of CI and analyze the mechanisms of action of several classes of medications currently used. We also suggest possible therapies and discuss the latest reports, which may lead to the discovery of novel pharmacological targets for future anti-CI drugs to be used in the clinical treatment.
Export Options
About this article
Cite this article as:
Mosinska Paula and Fichna Jakub, Ischemic Colitis: Current Diagnosis and Treatment, Current Drug Targets 2015; 16 (3) . https://dx.doi.org/10.2174/1389450116666150113120549
DOI https://dx.doi.org/10.2174/1389450116666150113120549 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Biologics and the Cardiovascular System: A Double-Edged Sword
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry HIF Prolyl 4-Hydroxylases and their Potential as Drug Targets
Current Pharmaceutical Design The Roles of Corticotropin Releasing Factor (CRF) in Responses to Emotional Stress: Is CRF Release a Cause or Result of Fear/Anxiety?
CNS & Neurological Disorders - Drug Targets Sodium Benzenesulfinates: Novel and Effective Organo Catalyst for Three Component Synthesis 5,6,7,8-Tetrahydro-4H-chromene Derivatives Under Ultrasound Irradiation
Letters in Organic Chemistry Novel Antibody Therapeutics Targeting Mesothelin In Solid Tumors
Clinical Cancer Drugs A2A Receptor Ligands: Past, Present and Future Trends
Current Topics in Medicinal Chemistry Inhibition of Endotoxin Response by Synthetic TLR4 Antagonists
Current Topics in Medicinal Chemistry Relative Survival Benefit and Morbidity with Fluids in Severe Sepsis - A Network Meta-Analysis of Alternative Therapies
Current Drug Safety Comparing the Molecular Pharmacology of CGRP and Adrenomedullin
Current Protein & Peptide Science Therapeutic Potential of Metabotropic GABA (GABAB) Receptors and their Effector Ion Channels
Central Nervous System Agents in Medicinal Chemistry Developing Pharmacotherapies for Cannabis and Cocaine Use Disorders
Current Neuropharmacology Cardiotoxicity of 5-Fluorouracil
Cardiovascular & Hematological Agents in Medicinal Chemistry Heart Failure Models: Traditional and Novel Therapy
Current Vascular Pharmacology Integrating Pharmacogenetics for Assessment of Herb-Drug Interactions: Has the Time Come?
Current Pharmacogenomics and Personalized Medicine A PHACES Syndrome Unmasked by Propranolol Interruption in a Tetralogy of Fallot Patient: Case Report and Extensive Review on New Indications of Beta Blockers
Current Medicinal Chemistry Updated Acute Community-Acquired Pneumonia in Adults: Guidelines for Initial Antimicrobial Therapy Based on Local Evidence from the South American Working Group (Consensur II)
Current Respiratory Medicine Reviews Geriatric Depression - Review for Primary Care
Current Psychiatry Reviews Pharmacology of Ivabradine and the Effect on Chronic Heart Failure
Current Topics in Medicinal Chemistry Human Ghrelin: A Gastric Hormone with Cardiovascular Properties
Current Pharmaceutical Design New Approaches in the Management of Septic Shock
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents